Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.R. 985

BillFederalHouseIn Committee
To amend the Federal Food, Drug, and Cosmetic Act to ensure that eligible product developers have competitive access to approved drugs and licensed biological products, so as to enable eligible product developers to develop and test new products, and for other purposes.
About This Bill
Committee
Latest Action · February 5, 2019
Referred to the House Committee on Energy and Commerce.
Introduced
February 5, 2019
Cosponsors (4)
3D 1R
View PDF ↗
SummaryFull TextCommentsAnnotations

Summary

Highlight any text to annotate
Fair Access for Safe and Timely Generics Act of 2019 or the FAST Generics Act of 2019 This bill generally prohibits the license holder of a drug or biological product approved by the Food and Drug Administration from restricting availability of the drug or product for testing by a product developer seeking to develop a drug, generic drug, or biosimilar.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.